Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in:

Open Access 02-09-2024 | Type 1 Diabetes | Case Report

Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review

Authors: Xiaofang Zhang, Dihua Huang, Dajun Lou, Xuwei Si, Jiangfeng Mao

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Background

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening skin lesion triggered by hypersensitive drug reaction. They are characterized by extensive epidermal necrosis and skin exfoliation. Fulminant type 1 diabetes mellitus (FT1DM) is featured by a rapid-onset of hyperglycemia with ketoacidosis due to severely destroyed β-cell function. Fulminant type 1 diabetes mellitus as a sequela of SJS/TEN has rarely been reported.

Case presentation

We present a 73-year-old female patient who developed SJS/TEN skin allergic reaction after taking carbamazepine and phenytoin for 35 days. Then, hyperglycemia and diabetic ketoacidosis occurred 20 days after discontinuation of antiepileptic drugs. A very low serum C-peptide level (8.79 pmol/l) and a near-normal glycosylated hemoglobin level met the diagnostic criteria for fulminant T1DM. Intravenous immunoglobulin (IVIG) and insulin were promptly administered, and the patient recovered finally.

Conclusions

This rare case indicates that monitoring blood glucose is necessary in SJS/TEN drug reaction, and comprehensive therapy with rehydration, insulin, antibiotics, and IVIG may improve the prognosis.
Literature
1.
Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and Erythema Multiforme. Arch Dermatol. 1993;129:92–6.CrossRefPubMed
2.
3.
Mockenhaupt M, Viboud C, Dunant A, et al. Toxic epidermal necrolysis: Assessment of Medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol. 2008;128:35–44.CrossRefPubMed
4.
Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000;342:301–7.CrossRefPubMed
5.
Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007;3:36–45.CrossRefPubMed
6.
Song SO, Yun JS, Ko SH, et al. Prevalence and clinical characteristics of fulminant type 1 diabetes mellitus in Korean adults: a multi-institutional joint research. J Diabetes Investig. 2022;13:47–53.CrossRefPubMed
7.
Hosokawa Y, Hanafusa T, Imagawa A. Pathogenesis of fulminant type 1 diabetes: genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research. J Diabetes Investig. 2019;10:1158–64.CrossRefPubMedPubMedCentral
8.
Zhu B, Wu J, Chen G, et al. Fulminant type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature. Front Endocrinol. 2019;10:474.CrossRef
9.
Ardern-Jones MR, Mockenhaupt M. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol. 2019;19:283–93.CrossRefPubMed
10.
Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136:1387–97.CrossRefPubMed
11.
Guvenir H, Arikoglu T, Vezir E, et al. Clinical phenotypes of severe cutaneous drug hypersensitivity reactions. Curr Pharm Des. 2019;25:3840–54.CrossRefPubMed
12.
13.
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54:147–76.CrossRefPubMed
14.
Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49–54.CrossRefPubMed
15.
Mulvey JM, Padowitz A, Lindley-Jones M, et al. Mycoplasma pneumoniae associated with Stevens Johnson syndrome. Anaesth Intensive Care. 2007;35:414–7.CrossRefPubMed
16.
Maloney NJ, Ravi V, Cheng K, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol. 2020;59:e183–8.CrossRefPubMed
17.
Gu Y, Sebaratnam DF. Contextualising associations of SJS/TEN with COVID-19 and the vaccine. Burns. 2023;49:1776–7.CrossRefPubMed
18.
Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225–30.CrossRefPubMedPubMedCentral
19.
Imagawa A, Hanafusa T, Awata T, et al. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus. J Diabetes Investig. 2012;3:536–9.CrossRefPubMedPubMedCentral
20.
Onuma H, Tohyama M, Imagawa A, et al. High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome. J Clin Endocrinol Metab. 2012;97:E2277–81.CrossRefPubMed
21.
Kano Y, Tohyama M, Aihara M, et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Survey conducted by the Asian Research Committee on severe cutaneous adverse reactions (ASCAR). J Dermatol. 2015;4:276–82.CrossRef
22.
23.
Chiou CC, Chung WH, Hung SI, et al. Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol. 2006;54(2 Suppl):S14–7.CrossRefPubMed
24.
Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a Comprehensive Summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017;34:1235–44.CrossRefPubMedPubMedCentral
25.
de Prost N, Ingen-Housz-Oro S, Duong T, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: Epidemiology, risk factors, and predictive value of skin cultures. Med (Baltim). 2010;89:28–36.CrossRef
26.
Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and Meta-analysis. JAMA Dermatol. 2017;153:514–22.CrossRefPubMedPubMedCentral
Metadata
Title
Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review
Authors
Xiaofang Zhang
Dihua Huang
Dajun Lou
Xuwei Si
Jiangfeng Mao
Publication date
02-09-2024

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue

Research

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males

Research

The association between the neutrophil-to-lymphocyte ratio and type 2 diabetes mellitus: a cross-sectional study

Research

Crosstalk between skeletal muscle ratio and cholesterol metabolism disorders: a cross-section study

Research

Correlation between serum sex hormone-binding globulin levels and nutrition indicators and malnutrition exposure risk in men and postmenopausal women with type 2 diabetes

Research

Establishment and external validation of an early warning model of diabetic peripheral neuropathy based on random forest and logistic regression

Research

Characteristics, management and outcomes of primary hyperparathyroidism from 2009 to 2021: a single centre report from South Africa

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits